Aspirin/MI Prevention Patient Identification Process Sought By FDA
This article was originally published in The Tan Sheet
Executive Summary
The practical application of risk assessment scores to identify appropriate patients for aspirin therapy as primary myocardial infarction prevention will be addressed during a Dec. 8 1advisory committee meeting
You may also be interested in...
Bayer HOT Aspirin Study Interpretation Gets Lukewarm FDA Feedback
FDA's review of the studies used by Bayer to support an aspirin indication for primary prevention of myocardial infarction suggests "a substantially weaker result than is published," according to the agency
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC